Delivers advanced data analysis and visualization capabilities to support nonclinical scientists
PRINCETON, N.J.— 2023年8月28日 – Certara, Inc., a global leader in biosimulation, today announced the release of version 11.0 of the SEND Explorer® Product Family. SEND Explorer allows scientists to interactively investigate study data, to efficiently identify dose-response relationships and to effectively communicate data trends with other scientists.
SEND Explorer is a validated, web-based application that provides advanced viewing, data summarization, and visualization capabilities for nonclinical study data. Using SEND Explorer, scientists can generate single- and multi-study visualizations to make data-driven decisions and quickly address questions from development teams and regulatory authorities.
SEND Explorer v11.0 adds several new visualizations, incorporates additional features to leverage the value of historical preclinical study data, includes numerous enhancements requested by scientists, and provides functionality to support the latest updates to the SEND model (SEND V3.1.1).
Key SEND Explorer updates include the following:
- New visualization capabilities: Adds single-study survival plots, multi-study line graphs, summary by tissue for organ weights, and existing visualization enhancements to include additional subplot and query features.
- Additional user controls: Supports horizontal reference line(s) in Line Graph and Scatterplot views, Historical Control Overlay on Scatterplot Timecourse View, and Cross-Study query for Endpoints of Interest.
- Technology upgrades: Now supports SEND V3.1.1 and provides a user-friendly interface for configuration of Pristima data sources.
Learn more about SEND Explorer at https://www.certara.com/data-and-informatics/send-explorer-software/.
Certara（サターラ）について
サターラは、独自のバイオシミュレーション・ソフトウェア、技術、サービスを用いて医薬品開発を支援し、従来の創薬・医薬品開発の改善に貢献します。2,000社の製薬企業、主要学術機関、世界各国の規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。（62か国にてビジネス展開）
